BRISTOL-MYERS SQUIBB COMPANY

Lobbying for BRISTOL-MYERS SQUIBB COMPANY

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $1,250,000.00 expenses · posted Jan 20, 2026

Official filing document

Bills named in this filing 3

HR 1492
To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic can…
HR 4299
Protecting Patient Access to Cancer and Complex Therapies Act
HR 7635
CHARGE Act

Lobbying activity 5

Health Issues

H.R.1492, Ensuring Pathways to Innovation Cures (EPIC) Act Implementation of Inflation Reduction Act of 2022 ORPHAN Cures Act MINI Act H.R.4299, the Protecting Patient Access to Cancer and Complex Therapies Act of 2025

Medicare/Medicaid

Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions H.R.7635, the 340B PATIENTS Act

Taxation/Internal Revenue Code

Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions Discussions regarding OECD implementation

Intellectual Property Reform concerning bio-pharmaceutical industry

Trade (domestic/foreign)

International Reference Pricing/Most Favored Nation, including all bio-pharmaceutical issues

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.